ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2251

Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty

Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Infection, outcomes, surgery and tobacco use, Total Knee Arthroplasty (TKA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

To our knowledge, well-designed studies that have examined the risk of post-arthroplasty implant-related complications after TKA with tobacco use are lacking.  Our objective was to assess the effect of current tobacco use on surgical outcomes after primary TKA.   We hypothesized that current tobacco use will be associated with an increased risk of infection, revision and wound complications after primary TKA. 

Methods:

This observational cohort study included all patients who underwent primary TKA at the Mayo Clinic from 2010 to 2013 and had tobacco use status documented in the Mayo Clinic’s nursing database.  Current tobacco use status was the predictor of interest.  It was defined based on the documentation of cigarette, cigar, pipe or smokeless tobacco use in the nursing database.  Current smokers were defined as people who were using cigarettes, cigars, pipes or smokeless tobacco at the time of their surgery.  They were compared to current non-smokers and former smokers with regards to post-TKA complications. 

Results:

Tobacco use data at the time of TKA were available for 4,227 (95%) TKA patients and not available for 249 (5%) of the patients; mean age (67 vs. 66), BMI (33 vs. 33) and Charlson index (1.5 vs. 1.4) were similar for patients with and without tobacco use data.

There were 228 current tobacco users (5%) and 4,049 non-users (95%) among patients who underwent primary TKA.  Compared to the non-users, current tobacco users who underwent primary TKA were more likely to be male, have higher Charlson index and less likely to be older than 80 years (p<0.01; reference ≤60 years).  No significant differences in BMI, ASA class or implant fixation were noted.  

Compared to non-smokers, smokers had 2.51 times higher hazard of any revision after primary TKA (p=0.02; Table 1). Rates of revision for infection, wound complications  and any infection showed a trend towards statistical significant with hazard ratios of 2.59 (p=0.07) ,1.84 (p=0.10) and 1.94 (p=0.12), respectively.  Rates of deep infection, superficial infection and periprosthetic fracture were higher for current smokers, but were not significantly different between current smokers and non-smokers. 

Conclusion:

Current tobacco use was a risk factor for poor postoperative outcomes after total knee arthroplasty, including higher revision rates and the risk of wound complications.  Perioperative smoking cessation efforts need to be incorporated into routing post-TKS care to prevent these complications after this elective surgery, aimed at improving patient’s quality of life.  

Table 1. Kaplan-Meier survival analyses for current smokers compared to current non-smokers (former smokers and never smokers)

Endpoint

Variable

# events

1 year (95% CI)

2 years (95% CI)

HR (95% CI)

p-value

Any revision

Current tobacco user

7

97.8 (95.3,100)

93.3 (88.5,98.4)

2.51 (1.14,5.54)

0.02

 

Past user or never used

50

98.7 (98.3,99.2)

97.7 (97.0,98.4)

1.0 (ref)

 

 

Revision for aseptic loosening

Current tobacco user

0

100

100

1.99 (0.08,52.2)

0.68

 

 Past user or never used

4

100 (99.9,100)

99.8 (99.6,100)

1.0 (ref)

 

 

Revision for infection

Current tobacco user

4

100

95.4 (91.1,99.9)

2.59 (0.92,7.31)

0.07

 

 Past user or never used

28

99.1 (98.6,99.5)

98.7 (98.2,99.2)

1.0 (ref)

 

 

Revision for peri-prosthetic fracture

Current tobacco user

0

100

100

3.59 (0.09,147.8)

0.50

 

 Past user or never used

2

99.9 (99.8,100)

99.9 (99.7,100)

1.0 (ref)

 

 

Complication deep infection

Current tobacco user

3

99.5 (98.5,100)

97.2 (93.3,100)

1.76 (0.54,5.77)

0.35

 

Past user or never used

31

98.9 (98.5,99.4)

098.6 (98.1,99.1)

1.0 (ref)

 

 

Complication superficial infection

Current tobacco user

3

98.3 (96.5,100)

98.3 (96.5,100)

2.12 (0.64,7.01)

0.22

 

Past user or never used

25

99.2 (98.8,99.5)

99.2 (98.8,99.5)

1.0 (ref)

 

 

Complication any  infection

Current tobacco user

6

97.8 (95.7,100)

95.5 (91.8,99.4)

1.94 (0.83,4.52)

0.12

 

 Past user or never used

56

98.1 (97.6,98.6)

97.8 (97.2,98.4)

1.0 (ref)

 

 

Complication wound complications

Current tobacco user

8

95.2 (92.0,98.6)

95.2 (92.0,98.6)

1.84 (0.88,3.8)

0.10

 

 Past user or never used

77

97.5 (97.0,98.1)

97.5 (96.9,98.0)

1.0 (ref)

 

 

Complication peri-prosthetic fracture

Current tobacco user

2

99.1 (97.9,100)

99.1 (97.9,100)

1.15 (0.27,4.78)

0.85

 

Past user or never used

31

99.2 (98.9,99.5)

99.0 (98.6,99.4)

1.0 (ref)

 

 


Disclosure: J. A. Singh, Takeda, Savient, 2,Takeda, Savient, merz, Regeneron, Allergan, Crealta, Bioiberica, 5;

To cite this abstract in AMA style:

Singh JA. Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/current-tobacco-use-and-the-rates-of-postoperative-complications-after-total-knee-arthroplasty/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/current-tobacco-use-and-the-rates-of-postoperative-complications-after-total-knee-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology